- JP-listed companies
- Balance sheet
(504A) Balance sheet
Market cap
¥38.7B
P/E ratio
Innovacell develops cell therapy treatments for incontinence using patients' own muscle cells to restore damaged muscle function. The company has three products in clinical trials with potential first-mover advantage in this specialized field.
| 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Cash and cash equivalents | - | 1,097 | 1,961 | 4,101 |
| Total current assets | - | 1,900 | 2,317 | 4,496 |
| Property, plant and equipment, net | - | 457 | 474 | 543 |
| Total non-current assets | - | 504 | 518 | 596 |
| Total assets | - | 2,404 | 2,835 | 5,093 |
| Long-term debt, current | - | 336 | 77 | 87 |
| Total current liabilities | - | 728 | 512 | 432 |
| Total non-current liabilities | - | 3,414 | 4,279 | 5,291 |
| Total liabilities | - | 4,142 | 4,791 | 5,723 |
| Retained earnings | - | -5,927 | -6,284 | -8,366 |
| Stockholders' equity | -396 | -1,738 | -1,956 | -630 |